Global ACTH and GH Function Tests Market Size By Type (Blood, Urine), By Application (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 to 2032

The Global ACTH and GH Function Tests Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.85 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. The market is experiencing robust growth driven by the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the growing demand for early disease detection. Adrenocorticotropic hormone (ACTH) and growth hormone (GH) function tests are essential tools in diagnosing pituitary and hypothalamic disorders, offering clinicians critical insights into hormonal imbalances and endocrine system performance.

Drivers:

Increasing Prevalence of Endocrine Disorders:

The growing incidence of hormonal conditions such as Addison's disease, Cushing’s syndrome, and growth hormone deficiency is significantly propelling the demand for ACTH and GH function tests. With increasing awareness and early screening efforts, diagnostic procedures are becoming more routine, boosting market growth.

Advancements in Diagnostic Technologies:

Innovations such as high-sensitivity immunoassays, point-of-care testing platforms, and fully automated hormone analyzers are streamlining the diagnostic process, improving test accuracy, and expanding accessibility across healthcare settings.

Rising Geriatric Population and Health Awareness:

Aging populations, particularly in developed countries, are more prone to endocrine dysfunctions, thereby elevating the demand for function tests. Growing health awareness and preventive healthcare practices are further fueling the demand.

Restraints:

High Cost of Advanced Diagnostic Tests:

Despite technological progress, the cost of comprehensive hormonal testing remains high, especially when coupled with follow-up evaluations and imaging, which may hinder adoption in cost-sensitive markets.

Limited Accessibility in Emerging Economies:

In low- and middle-income regions, underdeveloped healthcare infrastructure and lack of trained personnel can restrict the utilization of ACTH and GH tests, especially in rural and underserved areas.

Opportunity:

Expansion of Personalized Medicine and Endocrinology Research:

The market is poised to benefit from ongoing research in precision diagnostics and endocrinology. Increased focus on individualized hormone therapy and tailored treatment regimens will likely boost test volumes.

Integration of AI in Laboratory Testing:

Emerging integration of artificial intelligence and machine learning for predictive diagnostics and lab automation holds the potential to reduce costs, increase throughput, and enhance clinical decision-making.

Market by System Type Insights:

By system type, the Immunoassay Analyzers segment accounted for the largest share in 2023. These systems offer rapid and accurate hormone quantification, which is critical for ACTH and GH tests. With increasing automation and the adoption of high-throughput platforms, this segment is projected to maintain its dominance throughout the forecast period.

Market by End-Use Insights:

Hospitals emerged as the largest end-use segment in 2023, contributing to over 45% of total revenue. Hospitals often serve as the primary point of care for endocrine diagnostics due to their access to full-scale laboratories and specialist endocrinologists. Diagnostic laboratories and specialty clinics are also expected to see increased test volume as outpatient services expand.

Market by Regional Insights:

North America dominated the global ACTH and GH function tests market in 2023, driven by advanced healthcare systems, strong reimbursement frameworks, and widespread awareness. Europe followed closely, benefiting from government-supported endocrine health programs. Asia-Pacific is expected to witness the highest CAGR during the forecast period, with countries like China and India investing heavily in healthcare diagnostics and chronic disease management.

Competitive Scenario:

Key players in the Global ACTH and GH Function Tests Market include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, Bio-Rad Laboratories, and DiaSorin S.p.A. These companies are actively investing in R&D, expanding their diagnostic portfolios, and pursuing strategic partnerships.

Notable Developments:

In 2023, Siemens Healthineers launched a new high-sensitivity ACTH test compatible with its ADVIA Centaur systems, enhancing real-time diagnostics.

Abbott Laboratories partnered with a leading endocrinology research institute in 2024 to co-develop next-generation GH detection kits.

Roche Diagnostics announced the global rollout of its AI-powered hormone test interpretation system in 2025, aiming to support rapid clinical decision-making.

Scope of Work – Global ACTH and GH Function Tests Market

FAQs

1. What is the current market size of the Global ACTH and GH Function Tests Market?

The market size was valued at USD 1.1 billion in 2023.

2. What is the major growth driver of the Global ACTH and GH Function Tests Market?

The primary growth driver is the increasing prevalence of endocrine disorders and demand for early diagnosis.

3. Which is the largest region during the forecast period in the Global ACTH and GH Function Tests Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to witness the fastest growth.

4. Which segment accounted for the largest market share in the Global ACTH and GH Function Tests Market?

The Immunoassay Analyzers system type segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global ACTH and GH Function Tests Market?

Key players include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Danaher Corporation, and Thermo Fisher Scientific.